Filter posts

2018 BIO Investor Forum Wraps Up

As the stock market continued its volatile swings this week, investors at the BIO Investor …

BIO Investor Forum Explores “Digiceuticals” as a New Class of FDA-Approved Therapeutics

Within the past year, the FDA has launched a provider pre-certification program as a pilot …

A Patient-Centric Approach to Investing & Partnering

Thursday’s Plenary Luncheon Fireside Chat at the 2018 BIO Investor Forum (BIF) featured two industry leaders: …

Lessons from “View from the Board: Responding to an Acquisition Offer”

The “View from the Board: Responding to an Acquisition Offer” panel at the 2018 BIO …

On Track for a Record Breaking 2018 – #BIF18 Opening Plenary

Despite some recent market volatility, the industry is well positioned for long-term growth and success. …

How Companies are Using Microbiome-Based Therapies to Improve Patient Outcomes

On Wednesday morning at the BIO Investor Forum, leaders from six companies at the forefront …

Innovation Intersecting with Investing – Welcome to the BIO Investor Forum

Today marks the 17th opening of the BIO Investor Forum—a place where emerging biotech companies, …

Investment Market Good for Deal-making at #BIF18

As we move into the final quarter of 2018, we reflect on a year with …

Digital Health Innovation to be Spotlighted at the BIO Investor Forum

Is your company trying to expand into “digiceuticals” or digital therapeutics? Are you looking to …

Bull Market Bodes Well for #BIF18

The rapid pace of scientific discovery, FDA approvals, commercialization of medicines held long in pipelines, …